Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). 詳細を表示
GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide...
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...
Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.05 | -11.017838405 | 9.53 | 9.95 | 8.4 | 2804412 | 8.87713439 | CS |
| 4 | 1.428738 | 20.2621601637 | 7.051262 | 10.88 | 6.9809 | 3289652 | 8.90191571 | CS |
| 12 | 1.32 | 18.4357541899 | 7.16 | 11.16 | 5.86 | 2968326 | 8.07035145 | CS |
| 26 | 2.375 | 38.9025389025 | 6.105 | 11.16 | 5.29 | 3115460 | 7.3646222 | CS |
| 52 | 0.845 | 11.0674525213 | 7.635 | 14.84 | 5.29 | 4124679 | 8.80875212 | CS |
| 156 | -0.59 | -6.50496141125 | 9.07 | 23.49 | 2.09 | 2903780 | 8.12839144 | CS |
| 260 | 6.75 | 390.173410405 | 1.73 | 35.1 | 1.6 | 2507818 | 9.78979454 | CS |
Mark102
2週前
Mark102
4月前
Mark102
4月前
Mark102
5月前
Mark102
5月前
Mark102
6月前
girlfriend
6月前
Mark102
6月前
Mark102
6月前
brfv11
6月前
Mark102
6月前
Mark102
6月前
brfv11
6月前
akamaii
7月前
akamaii
8月前
Mt. Blanc
8月前
Mt. Blanc
9月前
Monksdream
9月前
Monksdream
9月前
saigai
9月前
Mark102
9月前
Mark102
9月前
saigai
9月前
saigai
9月前
Mt. Blanc
10月前
saigai
10月前
saigai
10月前
saigai
10月前
saigai
10月前
saigai
11月前
saigai
11月前
murocman
11月前
AGORDON
11月前
Mark102
11月前
saigai
11月前
Mark102
11月前
saigai
11月前
Mark102
11月前
saigai
11月前
saigai
11月前
Mark102
11月前
1hot toddy
11月前
Bud-Wiser
11月前
1hot toddy
12月前
eyeownu
12月前
1hot toddy
12月前
Mark102
12月前
1hot toddy
12月前
eyeownu
12月前
1hot toddy
1年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
